MorphoSys AG sell DirectorDealer
Start price
06.08.15
/
50%
€72.99
Target price
20.01.16
€65.69
Performance (%)
-43.01%
End price
20.01.16
€41.60
Summary
This prediction ended on 20.01.16 with a price of €41.60. The SELL prediction by DirectorDealer for MorphoSys AG performed very well with a performance of -43.01%. DirectorDealer has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | -1.476% | -1.476% | 225.451% | -6.669% |
| iShares Core DAX® | -0.922% | -1.078% | 12.165% | 16.796% |
| iShares Nasdaq 100 | 0.371% | -0.556% | 38.622% | 49.370% |
| iShares Nikkei 225® | 2.224% | -2.825% | 19.015% | 4.643% |
| iShares S&P 500 | -0.026% | -0.788% | 28.485% | 42.479% |
Comments by DirectorDealer for this prediction
In the thread Morphosys AG diskutieren
Director Dealing: Verkauf
Director Dealing / Insider Verkauf von Schottelius, Dr. Arndt (Geschäftsführendes Organ)
- Handelstag: 03.06.15
- Volumen: 356457 €
- Meldender: Schottelius, Dr. Arndt
.
(Durch neue Einschätzung ersetzt)